Quick Answer
CRESCENT BIOPHARMA, INC. reported Cash and Equivalents of $213.19 million for fiscal year 2025.
CRESCENT BIOPHARMA, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $213.19M | +513.2% |
| 2024 | $34.77M | -16.8% |
| 2023 | $41.79M | -12.7% |
| 2022 | $47.87M | -47.0% |
| 2021 | $90.25M | -34.1% |
| 2020 | $137.04M | -13.4% |
| 2019 | $158.20M | -24.6% |
| 2018 | $209.92M | +69.4% |
| 2017 | $123.92M | +209.5% |
| 2016 | $40.04M | -14.4% |
| 2015 | $46.80M | -15.2% |
| 2014 | $55.20M | +2288.9% |
| 2013 | $2.31M | -86.7% |
| 2012 | $17.37M | -38.3% |
| 2011 | $28.17M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $133.26M | +826.0% | +2273.7% |
| March 31, 2025 | $5.61M | -82.1% | -83.9% |
| December 31, 2024 | $34.77M | -16.8% | +141.6% |
| September 30, 2024 | $14.39M | -70.9% | -35.7% |
| June 30, 2024 | $22.39M | -61.4% | -28.4% |
| March 31, 2024 | $31.28M | -51.9% | -25.2% |
| December 31, 2023 | $41.79M | -12.7% | -15.4% |
| September 30, 2023 | $49.41M | -4.3% | -14.9% |
- CRESCENT BIOPHARMA, INC. showed an increase of +513.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, CRESCENT BIOPHARMA, INC.’s cash and equivalents has grown by 656.7% (from $28.17 million to $213.19 million).
- The most recent figure is from CRESCENT BIOPHARMA, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: